

Effective April 1st, 2024

ADSTILADRIN has established an Average Sales Price (ASP) in accordance with the guidelines set forth by the Centers for Medicare and Medicaid Services (CMS) Part-B.

This determination is a significant milestone for Ferring Uro-Oncology and represents our commitment to providing transparency and value to our customers.

Per CMS, the allowable amount of reimbursement for products under Part-B is $ASP + 6\%$.

You may find ASP information listed on the [CMS ASP Pricing File](#)